A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Risperidone (Primary)
  • Indications Alzheimer's disease; Dementia; Vascular dementia
  • Focus Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 25 Jul 2016 New trial record
    • 07 Jul 2016 Results of pooled analysis from 6 trials (USA-63, INT-24, AUS-5, USA-232, BEL-14 and INT-83) published in the British Journal of Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top